Shanghai Rendu Biotechnology Co. Ltd. A Total Liabilities
Shanghai Rendu Biotechnology Co. Ltd. A total liabilities. Based on the latest financial reports, Shanghai Rendu Biotechnology Co. Ltd. A (688193) has total liabilities worth CN¥65.45 Million CNY (≈ $9.58 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Shanghai Rendu Biotechnology Co. Ltd. A (688193) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shanghai Rendu Biotechnology Co. Ltd. A (2019–2025)
Total liabilities of Shanghai Rendu Biotechnology Co. Ltd. A from 2019 to 2025. This chart illustrates how Shanghai Rendu Biotechnology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.
Shanghai Rendu Biotechnology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shanghai Rendu Biotechnology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zoy Home Furnishing Co Ltd
SHG:603709
|
China | CN¥990.70 Million |
|
Arima Real Estate SOCIMI SA
MC:ARM
|
Spain | €256.53 Million |
|
Nerdwallet Inc
NASDAQ:NRDS
|
USA | $92.20 Million |
|
Is Finansal Kiralama AS
IS:ISFIN
|
Turkey | TL77.20 Billion |
|
Toya SA
WAR:TOA
|
Poland | zł173.66 Million |
|
Zhejiang Heda Technology Co Ltd
SHG:688296
|
China | CN¥328.22 Million |
|
Motech Industries Co Ltd
TWO:6244
|
Taiwan | NT$5.26 Billion |
|
Anton Oilfield Services Group
F:5AO
|
Germany | €7.83 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Shanghai Rendu Biotechnology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shanghai Rendu Biotechnology Co. Ltd. A (688193) total assets.
Liquidity & Leverage Metrics
Shanghai Rendu Biotechnology Co. Ltd. A Total Liabilities Ratios Explained
Shanghai Rendu Biotechnology Co. Ltd. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Rendu Biotechnology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Rendu Biotechnology Co. Ltd. A (2019–2025)
The table below shows the annual total liabilities of Shanghai Rendu Biotechnology Co. Ltd. A from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥76.26 Million ≈ $11.16 Million |
-7.54% |
| 2024-12-31 | CN¥82.48 Million ≈ $12.07 Million |
-10.32% |
| 2023-12-31 | CN¥91.97 Million ≈ $13.46 Million |
-27.77% |
| 2022-12-31 | CN¥127.34 Million ≈ $18.63 Million |
+40.15% |
| 2021-12-31 | CN¥90.86 Million ≈ $13.30 Million |
-5.11% |
| 2020-12-31 | CN¥95.75 Million ≈ $14.01 Million |
+163.00% |
| 2019-12-31 | CN¥36.41 Million ≈ $5.33 Million |
-- |
About Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of RNA molecular diagnostic technology and products. It offers products in the areas of reproductive health, bloodborne infections, respiratory infections, enterovirus infections, cancer early detection, and other areas; and AutoSAT, SuperSAT, and ultrasonic homogenizer. The company was founded in 2… Read more